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Background: A clear relationship between asthma and obesity has been reported, but the mechanisms remain
unclear. The aim of this study was to evaluate the influence of obesity on eosinophil activity (chemotaxis and
adhesion) in asthmatic children and adolescents compared with cells from healthy volunteers.
Methods: Asthmatic obese (AO), asthmatic non-obese (ANO), non-asthmatic obese (NAO) and non-asthmatic non-
obese (NANO) individuals were included in the present study. The chemotaxis of eosinophils after stimulation with
eotaxin (300 ng/ml), platelet-activating factor (10 μM; PAF) and RANTES (100 ng/ml) was performed using a
microchemotaxis chamber. The eosinophil peroxidase activity was measured to determine the adhesion activity of
eosinophils cultivated on fibronectin-coated plates. The serum leptin, adiponectin, TNF-α and IgE levels were
quantified using ELISA assays.
Results: The serum IgE levels and eosinophil counts were significantly higher in asthmatic (obese and non-obese)
individuals compared with non-asthmatic individuals (obese and non-obese). Spontaneous eosinophil chemotaxis
was greater in the AO group compared with either the ANO or NANO groups. The activation of eosinophils using
eotaxin and PAF increased eosinophil chemotaxis in the AO group. RANTES treatment increased eosinophil
chemotaxis in the NAO group compared with the NANO or ANO groups. The activation of eosinophils using
eotaxin significantly increased eosinophil adhesion in the AO group compared with other groups. The serum leptin
and TNF-α levels were higher in obese subjects (asthmatic and non-asthmatic), whereas the levels of adiponectin
did not significantly differ among these groups.
Conclusion: This study is the first to show increased eosinophilic activity (chemotaxis and adhesion) associated
with high serum leptin and TNF-α levels in atopic asthmatic obese children and adolescents compared with
non-obese healthy volunteers.Background
Recent meta-analyses [9,10], systematic reviews [11-13]
and cross-sectional [1-5], case control [6] and prospective
cohort [7,8] studies have demonstrated a relationship bet-
ween asthma and obesity. High body mass index (BMI)
has been associated with the increased incidence and
prevalence of asthma, asthma severity, reduced responses
to standard asthma medications, persistent symptoms and
poorly controlled disease [14-16], suggesting a specific
phenotype of asthma in obese individuals [17,18]. Obesity
increases the risk of asthma in both sexes and in different* Correspondence: milgrotta@hotmail.com
1Paediatric, State University of Campinas (UNICAMP), Campinas, São Paulo,
Brazil
Full list of author information is available at the end of the article
© 2013 Grotta et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orethnic groups. Several factors have been proposed, inclu-
ding obstruction of upper airways flows, gastroesophageal
reflux, inconsistent breathing from sleep-disorders, the
relationship between physical and sedentary activity, gene-
tics and the state of low-grade systemic inflammation
through obesity [19,20]. However, the exact mechanisms
responsible for the relationship between obesity and
asthma remain unknown.
Eosinophils are the primary effector cells responsible for
ongoing airway inflammation in atopic asthmatic indi-
viduals [21]. Evidence suggests that the recruitment of
eosinophils to sites of inflammation is a multifactorial and
multistep process, involving eosinophil-endothelial inter-
actions through adhesion molecules and the local gene-
ration of chemotactic agents that direct cell migrationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that the cytokines IL-3 and IL-5, granulocyte/macro-
phage-colony stimulating factor (GM-CSF) and adipo-
kines are involved in this process [22]. Eosinophils
migrate along the concentration gradient of chemoattrac-
tants, enter pulmonary circulation, marginate the vessel
wall and subsequently enter the interstitial spaces. How-
ever, the mechanisms by which obesity enhances the
clinical expression of asthma-related physiological changes
have not been fully elucidated. In murine models of diet-
induced obesity and allergic diseases, ovalbumin challenge
promotes hyperresponsiveness and eosinophilic inflamma-
tion associated with increased lung Th2 cytokines, serum
IgE and lung parenchyma remodelling [23-25]. However,
to the best of our knowledge, there are no studies
concerning in vitro eosinophilic activities (chemotaxis and
adhesion) in asthmatic obese individuals. Recent studies
reported that the number of eosinophils in sputum or
serum does not significantly differ between obese or
non-obese asthmatics [26,41]. Thus, we hypothesised that
the increase in obesity-associated systemic inflammatory
mediators activates eosinophils, thereby exacerbating
pulmonary inflammation, which is a direct component of
asthma pathophysiology. Therefore, the aim of this study
was to evaluate the influence of obesity on peripheral
blood eosinophil functions (chemotaxis and adhesion) in
asthmatic children and adolescents.
Methods
Subjects
A cross-sectional study was performed with 6-18-year-
old outpatients from the Paediatric Asthma Clinic of
State University of Campinas (UNICAMP). This study was
approved through the Ethics Committee of State University
of Campinas (UNICAMP). – (Agreement 352/2010). All
patients and parents or guardians provided informed con-
sent before beginning the study.
We selected four groups of individuals, namely asthmatic
obese (AO, n = 16), asthmatic non-obese (ANO, n = 16),
non-asthmatic obese (NAO, n = 5) and non-asthmatic
non-obese (NANO, n = 5) individuals. The asthma diag-
nosis was established according to the criteria of the
American Thoracic Society-European Respiratory Society
(ATS-ERS) [27], and the degree of asthma was classified
according to the Global Initiative for Asthma (GINA) as
intermittent, mild persistent, moderate persistent and
severe persistent asthma [28]. All patients were atopic and
sensitised to common perennial inhaled allergens, as
evaluated through skin-prick tests. The patients received
regular follow-up examinations at the paediatric pulmo-
nology outpatient clinic, with asthma treated using inhaled
corticosteroids (ICS), according to GINA [28] that is
400 mcg/day for mild asthma, 400 mcg ICS plus 12 mcg
long-acting beta agonist (LABA) for moderate asthma and800 mcg/day ICS plus 24 mcg/day LABA for severe
asthma. The patients were not smokers.
Obesity was defined as a body mass index (weight
(kg)/ height (m2)) above 95 percentile, according to the
NCHS (National Centre for Health Statistics) BMI curve
[29]. The control group (NANO) comprised healthy
volunteers with normal lung function and without diag-
nostic criteria for asthma and obesity. The non-asthmatic
obese group (NAO) did not present diagnostic criteria for
asthma, but exhibited BMIs above the 95th percentile. In
healthy children/adolescents, due to the smaller number
of blood eosinophils, a higher volume of blood (60 ml)
was required to perform the functional assays in vitro;
therefore, for ethical reasons, 5 individuals were included
in these groups. The exclusion criteria included children
younger than 6 years old due to their inability to perform
the lung function test and the presence of co-morbidities,
respiratory infections or uncontrolled asthma during the
previous 4 weeks. All patients were treated with anthel-
mintic albendazole at 400 mg (10 ml) in a single dose for
one month before beginning the study, excluding eosino-
philia due to parasitosis. The serum cholesterol, trigly-
cerides, fasting glucose and IgE levels and circulating
eosinophil counts were obtained from each patient.
Eosinophil isolation
The eosinophils were isolated from peripheral blood as
previously described [30]. Briefly, 30 ml of blood, collected
in 3.13% (w/v) sodium citrate, was diluted 1:1 using phos-
phate buffered saline (PBS), and 35 ml of diluted blood was
overlaid onto a 15-ml Percoll gradient (Sigma Chemical
Co-USA). The gradients were centrifuged at 1000 g for
23 min at 4°C (Hermle model Z360k centrifuge, Germany),
and the pellet containing red cells and granulocytes were
collected. The red cells were lysed using lysing buffer, and
the remaining granulocytes were washed. Another lysis
was performed using distilled water. Subsequent to centri-
fugation at 400 g for 10 min at 4°C, and subsequently the
pellet was incubated with anti-CD16 immunomagnetic
microbeads for 30 min before passing on a steel-matrix
column in a magnetic field, and the CD16-negative eosino-
phils were collected. The eosinophils were resuspended in
minimum essential medium (MEM), pH 7.2 (> 92% eosi-
nophils; the contaminating cells were mononuclear cells).
Chemotaxis assays
The eosinophils were resuspended at a concentration of
4 × 106 cells/ml in minimum essential medium (MEM),
and migration assays were performed using a 48-well
microchemotaxis chamber [31]. The bottom wells of the
chamber were filled with the chemoattractants eotaxin
(300 ng/ml), PAF (10 μM) and RANTES (100 ng/ml) or
MEM (control), and the upper wells were filled with eo-
sinophils (50 μl). The bottom and upper cells were
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Pleasanton, CA, USA). The chamber was subsequently
incubated for 1 h at 37°C (5% CO2). At the end of the
incubation period, the filter was removed, washed, stained
with Diff- Quik® (Baxter Healthcare Corporation, USA),
and mounted on a glass slide. The incubations were
performed in triplicate, and migration was determined by
counting the eosinophils that migrated completely through
the filter in five random high-powered fields (HPF).
Eosinophil adhesion assay
The adhesion assay was performed as previously described
[32]. Briefly, 96-well plates (Maxisorp, Nunc, Roskilde,
Denmark) were prepared by coating individual wells with
60 μl of fibronectin overnight at 4°C. The wells were
washed twice with PBS before blocking the non-coated
sites using 0.1% (w/v) bovine serum albumin (BSA) for
60 min at 37°C. The wells were washed twice with PBS,
and the plates were dried. The eosinophil suspension was
subsequently incubated for 30 min at 37°C (5% CO2) with
the adhesion stimulus eotaxin (100 ng/ml). The treated
eosinophils were added at a volume of 50 μl of MEM
(7 × 104 cells/ml) to the coated wells of a 96-well plate.
The cells were incubated to adhere to the wells for 30 min
at 37°C (5% CO2). After incubation, the non-adhered cells
were removed, and the remaining cells were washed twice
with PBS. Fifty microliters of MEM was added to each
well and varying concentrations of the original cell sus-
pension (in MEM) were added to the empty wells to form
a standard curve. The eosinophil adhesion was calculated
after measuring the residual eosinophil peroxidase (EPO)
activity of adherent cells. Briefly, EPO substrate (Sigma
Chemical Co., St Louis, MO) was added to each well and
incubated for 30 min at room temperature. The reaction
was terminated using 25 μL H2SO4 (4 M) per well, and
the absorbance was measured at 490 nm in a microplate
reader (Multiscan MS; Labsystems, Helsinki, Finland).
The adherence was calculated by comparing the absorb-
ance of the unknown samples to that of a standard curve.
Serum leptin, adiponectin and TNF-α levels
After centrifugation, 2 ml aliquots of serum were frozen
(−60°C). The leptin, adiponectin and TNF-α levels were
measured in serum using commercially available enzyme-
linked immunosorbent assay (ELISA) kits according to the
manufacturer’s instructions (Millipore, St Charles, Missouri,
USA). The leptin and adiponectin levels ranged from 0.5 to
100 and 1.56 to 100 ng/mL, respectively. Low and high
quality controls were assayed in parallel in each assay.
Measurement of lipid levels, fasting glucose and IgE
The levels of total cholesterol, high-density lipoprotein
(HDL) and triglycerides in serum were measured using
commercially available kits (Roche Laboratories, SãoPaulo, Brazil). The low-density lipoprotein (LDL) levels
were calculated according to the manufacturer’s instruc-
tions. The blood glucose concentration was measured
(Accu-Check Performa, Roche Diagnostics, Indianapolis,
IN, USA). The IgE kit was obtained from Dade Behring
(Marburg, USA).
Statistical analysis
The sample size was derived from a pilot project including
a small group of obese and non-obese subjects. The study
was designed to have 80% power to detect a significant
difference between obese and non-obese individuals, with
a type I error of 5%. The data are presented as the mean
values ± SEM of n experiments. The Instat (GraphPad
software) programme and the SAS System for Windows
(Statistical Analysis System, version 9.2, SAS Institute, Inc,
2002–2008, Cary, NC, USA) were used for the statistical
analysis. One-way ANOVA followed by Turkey`s test was
used to analyse cholesterol, triglycerides, fasting glucose,
serum IgE, eosinophil counts, chemotaxis, adhesion, and
the leptin and adiponectin levels. The adiponectin
levels were analysed using ANOVA, followed by the
Kruskal-Wallis test. P < 0.05 was accepted as statisti-
cally significant.
Results
Subject characteristics and serum measurements
The characteristics of the study subjects are presented in
Table 1. There were no differences in the age or sex
among the groups. The total cholesterol was elevated in
the obese groups (asthmatic and non-asthmatic) com-
pared with non-obese individuals (asthmatic and non-
asthmatic; P = 0.0009). The levels of HDL, VLDL and
LDL-cholesterol, triglycerides and fasting glucose were
not significantly different between groups.
The serum IgE levels and eosinophil counts were sig-
nificantly higher in the asthmatic individuals (obese and
non-obese) compared with the non-asthmatic indivi-
duals (obese and non-obese; P = 0.0007 for IgE; P = 0.024
for eosinophil counts) (Table 1).
Eosinophil chemotaxis to eotaxin, PAF and RANTES
Figure 1A shows that the spontaneous eosinophil
chemotaxis (non-activated cells; MEM) was increased in
the asthmatic obese (AO) group compared with either
asthmatic or non-asthmatic non-obese individuals (NAO
and NANO groups, respectively).
The activation of eosinophils using eotaxin (300 ng/ml;
Figure 1B) and PAF (10 μM; Figure 1C) also increased cell
chemotaxis in the asthmatic obese (AO) group compared
with ANO and NANO groups. The increased eotaxin-
and PAF-induced chemotaxis in AO individuals did not
significantly differ from that observed in the NAO groups
(Figure 1B,C). With regard to RANTES (100 ng/ml;










N 16 5 16 5
Age (years) 10 11 9.5 28 0.6804
Sex (% males) 56% 40% 62.5% 40% 0.7832
Total cholesterol 176 214.2(a) 136.75(a) 111.8 0.0009
BMI 28.16 ± 4.46 31.54 ± 4.12 18.79 ± 3.39 21.55 ± 1.63 0.0050
FVC 102.5 102.8 94 90 0.3172
FEV1 91 102 86 98 0.2581
FEV1/FVC 88 92.6 87.5 93 0.0752
HDL 42.5 40.2 46.94 48 0.2919
VLDL 15.5 24 17 14.4 0.2356
LDL 82.0 146.6(b) 90.38(b) 71 0.0360
Tryglicerides 77.0 120.8 76.88 83.6 0.1617
Glucose (g/dL) 81.0 79 79.81 81.6 0.7901
IgE (U/mL) 653.5(c) 84.8 862.67(c) 89.8 0.0007
Blood eosinophil (%) 7.05(d) 5.06 8.31(d) 1.52 0.0024
Data presented as median or percentage (%) of subjects with the specified factor.
(a) and (b) p < 0.05 – versus to non-obese groups.









































































































Figure 1 Human eosinophil chemotaxis in asthmatic obese (AO), asthmatic non-obese (ANO), non-asthmatic obese (NAO) and non-
asthmatic non-obese (NANO) subjects in response to (A) minimum essential medium (MEM, 27 μL), (B) eotaxin (300 ng/ml), (C) PAF
(10 μM) and (D) RANTES (100 ng/ml). Eosinophils (4 × 106/ml /50 μl / well) were incubated for 1 h at 37°C in the microchemotaxis chamber,
and the filters were stained and mounted on a glass slide. Eosinophil migration was determined after counting the eosinophils that migrated
completely through the filter in five random high-powered fields (HPF; 1000 x) per well. The results are expressed as the mean migrated cells for
each individual (P values are shown in figure).
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non-asthmatic obese (NAO) group compared with either
non-asthmatic (NANO group) or asthmatic (ANO group)
non-obese individuals. No significant differences were
detected between the NAO and AO groups (Figure 1D).
Eosinophil adhesion to fibronectin-coated plates
Basal eosinophil adhesion to human fibronectin was simi-
lar among all groups (Figure 2A). The activation of eosi-
nophils with eotaxin (100 ng/ml) significantly increased
the adhesion of eosinophils in the AO group compared
with NANO, ANO and NAO subjects (Figure 2B).
Levels of leptin, adiponectin and TNF-α
Figure 3A shows that serum leptin levels were higher in
obese subjects (asthmatic and non-asthmatic) compared
with non-obese groups (NANO and ANO; P < 0.0001).
Serum adiponectin levels did not significantly differ
among the groups (Figure 3B). The serum TNF-α levels
were higher in obese subjects (asthmatic and non-
asthmatic) compared with non-asthmatic non-obese
subjects (P < 0.029; Figure 3C).
Discussion
The present study is the first to show increased eosino-
philic activity (chemotaxis and adhesion) in atopic obese
individuals associated with high serum leptin and TNF-α
levels in children and adolescents compared with non-
obese volunteers. The patients received regular follow-
up examinations in paediatric pulmonology outpatient
clinics, with asthma control and the regular use of inhaled
corticosteroids, according to severity classifications. Des-
pite the clinical control and lung function test, circulating
eosinophils in asthmatic obese individuals (AO group)
exhibited an increased level of pre-activation, as evidenced






















Figure 2 Adhesion of human eosinophils to fibronectin coated plates
non-obese (ANO), non-asthmatic obese (NAO) groups and healthy volunte
subsequently incubated to evaluate the adherence to fibronectin-coated w
percentages for each individual (P values are shown in figure).Eotaxin is the strongest and the most specific factor
for eosinophils, acting through interactions with CCR3
receptors [33]. The eosinophil counts in an infiltrated
organ are proportional to the eotaxin concentrations at
the inflammatory site [34-37], with poor asthma control
and increased symptom severity. In addition, we also
used the chemoattractants PAF and RANTES to evalu-
ate the eosinophil activity in all groups of individuals.
PAF is a well-known phospholipid mediator that regulates
a variety of physiopathological processes in different cell
types that might be important in the pathogenesis of
asthma [38]. RANTES, a product of activated T cells, is
elevated in the atopic and non-atopic asthmatic airways
and promotes eosinophil and T cell infiltration. The
expression of RANTES has been demonstrated in bron-
chial smooth muscle, eosinophils and T cells [39]. In the
present study, spontaneous chemotaxis (non-activated
cells) was elevated in asthmatic obese individuals com-
pared with asthmatic non-obese individuals. Similarly,
eotaxin- and PAF-induced eosinophil chemotaxis was
increased in asthmatic obese individuals compared with
asthmatic non-obese individuals. Interestingly, obesity
itself (in the absence of asthma) increased eosinophil
chemotaxis towards eotaxin and RANTES.
Adhesion molecules and chemokines play key roles in
selective eosinophil accumulation. The integrins macro-
phage adhesion molecule-1 (Mac-1, CD11b/CD18, αMβ2)
and very late antigen-4 (VLA-4, CD49d/CD29, α4β1) are
important for the firm adhesion of eosinophils to the
endothelium through the intercellular adhesion molecule
(ICAM)-1 and the vascular cell adhesion molecule
(VCAM)-1, respectively [39]. Both Mac-1 and VLA-4
integrins expressed in eosinophils bind to extracellular
matrix components, such as fibronectin [39]. The firm
adhesion of eosinophils to fibronectin is mediated through
the binding of eosinophil-expressed VLA-4 to the connec-






















. Eosinophils (7 × 104 cells/ml) of asthmatic obese (AO), asthmatics
ers (NANO) were incubated with MEM (A) and eotaxin (B), and





































































Figure 3 Leptin (A), adiponectin (B) and TNF-α (C) levels in the serum of asthmatic obese (AO), asthmatics non-obese (ANO), non-
asthmatic obese (NAO) groups and healthy volunteers (NANO). Adipokines and TNF-α levels were measured in the serum using the
commercially available enzyme-linked immunosorbent assay (ELISA) kits (P values are shown in figure).
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increased eotaxin-induced eosinophil adhesion in the
asthmatic obese group compared with the other groups.
Circulating leptin levels were directly correlated with
adipose tissue mass [40,41]. Leptin is also a pro-
inflammatory mediator that enhances systemic and
pulmonary inflammation [42]. Therefore, high levels of
leptin are essential in linking obesity to allergic airway
inflammation [43]. In human eosinophils obtained from
healthy volunteers, leptin up-regulated the cell surface
expression of the adhesion molecule ICAM-1, sti-
mulated the eosinophil chemokinesis and induced the
release of inflammatory cytokines [22]. Moreover, leptin
up-regulates TNF-α production and adhesion molecule
expression in endothelial cells [22]. Leptin exerts both
direct and indirect effects on eosinophil chemotaxis and
intracellular signalling. In physiological settings, leptin
might maintain eosinophil accumulation at inflamma-
tory foci [44]. In the present study, the serum leptin and
TNF-α levels were higher in obese individuals, irrespect-
ive of the presence of asthma, suggesting that leptin
might be involved in the priming of circulating eosino-
phils. The results of recent studies are inconclusive
regarding the independent association between serum
leptin concentrations and the risk for asthma. Studies
performed in children had significantly smaller sample
sizes, showing a positive association between these twofactors [42], while other studies showed no association
[45]. The adiponectin levels diminished with increased
adiposity and during the inflammatory response [40,43].
The anti-inflammatory activities of adiponectin has been
associated with the reduced production/activity of TNF-
α and the inhibition of IL-6 accompanied by the induc-
tion of the anti-inflammatory cytokines IL-10 and IL-1
receptor antagonist [40]. However, in the present study,
we did not observe statistically significant differences
among the groups, ruling out the possibility that
adiponectin regulate the in vitro activity of eosinophils.
A limitation of our study is that the healthy volunteers
comprising the control group (NANO) are older
(28 years) compared with AO (10 years), NAO (11 years)
and ANO (9.5 years) groups. Therefore, we cannot rule
out the possibility that the observed differences are due
to an age effect.
Conclusion
In conclusion, obesity associated with increased serum
leptin and TNF-α levels enhance eosinophil chemotaxis
and adhesion in asthmatic children and adolescents.
Despite effective asthma control with the regular use of
inhaled corticosteroids, there is an increased activity in
circulating eosinophils from obese asthmatics. Thus,
there is a pressing need to improve our understanding of
the mechanisms underlying the relationship between
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to improve the health outcomes of obese patients with
asthma.
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